MDM2 and cancer: Interestingly, SJ3149 also inhibited several TP53-altered cell lines, such as BT-20 and KU812, suggesting that CK1α degraders may offer potential therapeutic opportunities for cancers that are insensitive to MDM2 inhibitors.